Bacteriophage PA1Φ Targeting Actinobacillus pleuropneumoniae
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae lack effective alternatives, particularly in the context of antibiotic resistance and the need for eco-friendly solutions.
Innovation Solution
Development of bacteriophage PA1Φ, a specific bacteriophage with bactericidal activity against Actinobacillus pleuropneumoniae, which can infect and kill the bacteria, offering a prophylactic and therapeutic option for the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat Actinobacillus pleuropneumoniae infection, then bactericidal activity is achieved, but antibiotic resistance develops and harmful effects on normal flora occur
Solution Approach 1:
The patent applies segmentation by using a specific bacteriophage that targets only Actinobacillus pleuropneumoniae without affecting other bacteria. The phage infection process is divided into specific stages (adsorption, penetration, replication, lysis) that selectively eliminate the pathogen while preserving normal flora, thus resolving the contradiction between effective bactericidal activity and harmful effects on beneficial bacteria.
Solution Approach 2:
The patent implements local quality through the high specificity of bacteriophage PA1Φ for Actinobacillus pleuropneumoniae. The phage exhibits local quality in its host range, infecting only the target bacterium and leaving other microorganisms unaffected. This selective action eliminates the harmful effects on normal flora while maintaining reliable bactericidal activity against the pathogen.
2Object-generated harmful factors
If bacteriophage PA1Φ is used to treat Actinobacillus pleuropneumoniae, then targeted bactericidal activity is achieved without affecting normal flora, but the complexity of phage culture and purification increases
Solution Approach 1:
The patent applies self-service by utilizing the bacteriophage's ability to self-replicate and self-assemble within the host bacterium. The phage genome directs the synthesis of phage components inside Actinobacillus pleuropneumoniae cells, eliminating the need for external provision of phage particles. This self-service mechanism simplifies the production process while maintaining targeted bactericidal activity without affecting normal flora.
Solution Approach 2:
The patent implements parameter changes by optimizing culture conditions (temperature, pH, nutrient composition) to enhance phage production efficiency. By adjusting these parameters, the complex purification process is simplified, and high-titer phage suspensions are obtained with reduced contamination, thus resolving the contradiction between eliminating side effects and reducing process complexity.
3Reliability
If bacteriophage PA1Φ is deployed for prevention and treatment, then effective control of Actinobacillus pleuropneumoniae is achieved, but the limited specificity means only one phage type can target one bacterium
Solution Approach 1:
The patent applies universality by demonstrating that bacteriophage PA1Φ can infect multiple strains of Actinobacillus pleuropneumoniae with different serotypes. This multi-functional capability allows a single phage type to target various bacterial variants, expanding the host range while maintaining reliable bactericidal activity. This resolves the contradiction by showing that specificity does not limit versatility when the target organism has variant strains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Bacteriophage PA1Φ provides targeted bactericidal activity against Actinobacillus pleuropneumoniae without affecting normal flora, reducing side effects and offering a potential alternative to conventional antibiotics.
Implementation Method 1
A bacteriophage, or 'phage', is a very tiny microorganism that infects bacteria. Bacteriophages kill bacteria by entering bacterial host cells and replicating. When enough phage offspring are produced host cells will be broken open and die.
Implementation Method 2
When enough phage offspring are produced host cells will be broken open and die.
Data Source
AI summary
The present invention relates to a bacteriophage having bactericidal activity against Actinobacillus pleuropneumoniae. Bacteriophage PA1Φ can infect Actinobacillus pleuropneumoniae and kill the same bacteria and is characterized by the genome of 34,553 by represented by SEQ ID NO: 1.